Tenaya Therapeutics, Inc. TNYA 深 沪
等待开盘 03-26 09:30:00 美东时间
0.7224
-0.035
-4.62%
华盛通- 最 高0.804
- 今 开0.7792
- 成交量 371.34万股
- 最 低 0.721
- 昨 收 0.7574
- 总市值 1.56亿
- 52周最高 2.35
- 市盈率 静 --
- 换手率 1.72%
- 52周最低 0.36
- 委 比 78.79%
- 总股本 2.17亿
- 历史最高 32.00
- 量 比 1.15
- 振 幅 10.96%
- 历史最低 0.36
- 每 手 1
- 风险率 0.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tenaya Therapeutics Q4 EPS $(0.12) Beats $(0.13) Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 9.09 percent. This is a 57.14 percent increase over losses of $(0.28) per share
03-12 04:10
美股牛股 | 传与OpenAI合作+CEO大规模增持，TTD大涨超18%；石油股SOC暴涨超37%
传与OpenAI合作+CEO大规模增持，TTD大涨超18%；中东局势加剧引油价狂飙！石油股SOC暴涨超37%>>
03-06 16:48
Tenaya Therapeutics Collaborates With Alnylam Pharmaceuticals To Discover Human Genetic Targets For Potential Development Of Disease-modifying Treatments For Cardiovascular Diseases
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease,
03-05 21:34
美股牛股 | 矽晶电信飙升近30%，Q4营收同比大增17%；西南航空大涨18%
矽晶电信飙升近30%，Q4营收同比大增17%；摩丁制造大涨20%，分拆技术业务并与Gentherm合并，以优化公司结构；西南航空大涨18%，Q4每股收益及全年指引均超预期>>
01-30 18:27
Tenaya Therapeutics Issues Update On Clinical Development Programs And Outlines Strategic Priorities For 2026; Aims To Build On Positive 2025 Interim TN-201 Results In H1 2026
Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCMExpects to Report
01-09 21:38
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
2025-12-15 15:30
Tenaya Stock Plunges After $60 Million Equity Offering
Heart disease-focused Tenaya Therapeutics falls on high volume after pricing a $60 million offering and releasing new TN-401 data, while the FDA clears the TN-201 trial hold.
2025-12-13 02:56
Tenaya Therapeutics shares are trading lower after the company announced a proposed public offering.
Tenaya Therapeutics shares are trading lower after the company announced a prop...
2025-12-12 05:24
Tenaya Therapeutics announces proposed public offering
Tenaya Therapeutics (NASDAQ:TNYA) announced on Thursday that it intends to offer and sell units consisting of common stock and warrants to purchase shares of common stock. The company may also sell to...
2025-12-12 05:16
Tenaya Therapeutics Receives FDA Clearance To Resume MyPEAK‑1 Trial Of TN‑201 For MYBPC3‑Associated Hypertrophic Cardiomyopathy
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today
2025-12-12 05:07
